Chronic inflammatory disorders and risk of type 2 diabetes mellitus, coronary heart disease, and stroke : A population-based cohort study

Circulation

Volumn 130, Issue 10, 2014, Pages 837-844

  Dregan, Alex ^a,b   Charlton, Judith ^a   Chowienczyk, Phil ^c   Gulliford, Martin C ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^c KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Biomarker; Coronary disease; Diabetes mellitus; Inflammation; Stroke

Indexed keywords

C REACTIVE PROTEIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE DISEASE; BULLOUS SKIN DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; CHRONIC INFLAMMATORY DISORDER; CLINICAL EVALUATION; COHORT ANALYSIS; CONTROLLED STUDY; CROHN DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; ELECTRONIC MEDICAL RECORD; FEMALE; HAZARD RATIO; HUMAN; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOME ASSESSMENT; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSORIASIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; SYSTEMIC VASCULITIS; ULCERATIVE COLITIS;

BIOMARKER; CORONARY DISEASE; DIABETES MELLITUS; INFLAMMATION; STROKE;

ADULT; AGED; AGED, 80 AND OVER; AUTOIMMUNE DISEASES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CASE-CONTROL STUDIES; CHRONIC DISEASE; COHORT STUDIES; CORONARY DISEASE; DIABETES MELLITUS, TYPE 2; FEMALE; GREAT BRITAIN; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PSORIASIS; RHEUMATIC DISEASES; RISK FACTORS; STROKE;

EID: 84907598755     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.114.009990     Document Type: Article

References (49)

1. Crowson CS, Liao KP, Davis JM III, Solomon DH, Matteson EL, Knutson KL, Hlatky MA, Gabriel SE. Rheumatoid arthritis and cardiovascular disease. Am Heart J. 2013;166:622-628.e1.
2. Corrado E, Rizzo M, Coppola G, Fattouch K, Novo G, Marturana I, Ferrara F, Novo S. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17:1-11.
3. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA. 2006;296:1735-1741.
4. Khalid U, Hansen PR, Gislason GH, Lindhardsen J, Kristensen SL, Winther SA, Skov L, Torp-Pedersen C, Ahlehoff O. Psoriasis and new-onset diabetes: a Danish nationwide cohort study. Diabetes Care. 2013;36:2402-2407.
5. Watson DJ, Rhodes T, Guess HA. All-cause mortality and vascular events among patients with rheumatoid arthritis, osteoarthritis, or no arthritis in the UK General Practice Research Database. J Rheumatol. 2003;30:1196-1202.
6. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manson JE, Stampfer MJ, Curhan GC. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation. 2003;107:1303-1307.
7. Gustafsson JT, Simard JF, Gunnarsson I, Elvin K, Lundberg IE, Hansson LO, Larsson A, Svenungsson E. Risk factors for cardiovascular mortality in patients with systemic lupus erythematosus: a prospective cohort study. Arthritis Res Ther. 2012;14:R46.
8. Hollowell J. The general practice research database: quality of morbidity data. Population Trends. 1997:36-40.
9. Dregan A, Toschke MA, Wolfe CD, Rudd A, Ashworth M, Gulliford MC; eCRT Research Team. Utility of electronic patient records in primary care for stroke secondary prevention trials. BMC Public Health. 2011;11:86.
10. Gulliford MC, Charlton J, Ashworth M, Rudd AG, Toschke AM; eCRT Research Team. Selection of medical diagnostic codes for analysis of electronic patient records: application to stroke in a primary care database. PLoS One. 2009;4:e7168.
11. Yeung H, Takeshita J, Mehta NN, Kimmel SE, Ogdie A, Margolis DJ, Shin DB, Attor R, Troxel AB, Gelfand JM. Psoriasis severity and the prevalence of major medical comorbidity: a population-based study. JAMA Dermatol. 2013;149:1173-1179.
12. Wan J, Wang S, Haynes K, Denburg MR, Shin DB, Gelfand JM. Risk of moderate to advanced kidney disease in patients with psoriasis: population based cohort study. BMJ. 2013;347:f5961.
13. Ritchie SA, Connell JM. The link between abdominal obesity, metabolic syndrome and cardiovascular disease. Nutr Metab Cardiovasc Dis. 2007;17:319-326.
14. Bhattarai N, Charlton J, Rudisill C, Gulliford MC. Coding, recording and incidence of different forms of coronary heart disease in primary care. PLoS One. 2012;7:e29776.
15. Charlton J, Latinovic R, Gulliford MC. Explaining the decline in early mortality in men and women with type 2 diabetes: a population-based cohort study. Diabetes Care. 2008;31:1761-1766.
16. Danesh J, Whincup P, Walker M, Lennon L, Thomson A, Appleby P, Gallimore JR, Pepys MB. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. BMJ. 2000;321:199-204.
17. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med. 2005;352:1685-1695.
18. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr, Roccella EJ; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA. 2003;289:2560-2572.
19. Grundy SM. New cholesterol guidelines emphasize risk assessment. Am J Manag Care. 2002;suppl:1, 3.
20. Lindor KD, Dickson ER, Baldus WP, Jorgensen RA, Ludwig J, Murtaugh PA, Harrison JM, Wiesner RH, Anderson ML, Lange SM. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology. 1994;106:1284-1290.
21. Kelly PJ, Lim LL. Survival analysis for recurrent event data: an application to childhood infectious diseases. Stat Med. 2000;19:13-33.
22. 2+-ATPase in patients with advanced heart failure. Circulation. 2011;124:304-313.
23. Therneau MJ, Grambsch PM. Modeling Survival Data: Extending the Cox Model. New York, NY: Springer; 2000.
24. Pandeya N, Purdie DM, Green A, Williams G. Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am J Epidemiol. 2005;161:748-754.
25. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;96:13.
26. Sjölander A, Greenland S. Ignoring the matching variables in cohort studies: when is it valid and why? Stat Med. 2013;32:4696-4708.
27. Schmidt FL, Oh IS, Hayes TL. Fixed- versus random-effects models in meta-analysis: model properties and an empirical comparison of differences in results. Br J Math Stat Psychol. 2009;62(pt 1):97-128.
28. Maradit-Kremers H, Crowson CS, Nicola PJ, Ballman KV, Roger VL, Jacobsen SJ, Gabriel SE. Increased unrecognized coronary heart disease and sudden deaths in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum. 2005;52:402-411.
29. Thomas E, Symmons DP, Brewster DH, Black RJ, Macfarlane GJ. National study of cause-specific mortality in rheumatoid arthritis, juvenile chronic arthritis, and other rheumatic conditions: a 20 year followup study. J Rheumatol. 2003;30:958-965.
30. Azfar RS, Seminara NM, Shin DB, Troxel AB, Margolis DJ, Gelfand JM. Increased risk of diabetes mellitus and likelihood of receiving diabetes mellitus treatment in patients with psoriasis. Arch Dermatol. 2012;148:995-1000.
31. Armstrong EJ, Harskamp CT, Armstrong AW. Psoriasis and major adverse cardiovascular events: a systematic review and meta-analysis of observational studies. J Am Heart Assoc. 2013;2:e000062.
32. Samarasekera EJ, Neilson JM, Warren RB, Parnham J, Smith CH. Incidence of cardiovascular disease in individuals with psoriasis: a systematic review and meta-analysis. J Invest Dermatol. 2013;133:2340-2346.
33. Yarur AJ, Deshpande AR, Pechman DM, Tamariz L, Abreu MT, Sussman DA. Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol. 2011;106:741-747.
34. Emerging Risk Factors Collaboration. Analysis of individual data on lipid, inflammatory and other markers in over 1.1 million participants in 104 prospective studies of cardiovascular diseases. Eur J Epidemiol. 2007;22:839-869.
35. Danesh J, Collins R, Appleby P, Peto R. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA. 1998;279:1477-1482.
36. Hassan N, Dasgupta B, Barraclough K. Giant cell arteritis. BMJ. 2011;342:d3019.
37. Danesh J, Wheeler JG, Hirschfield GM, Eda S, Eiriksdottir G, Rumley A, Lowe GD, Pepys MB, Gudnason V. C-reactive protein and other circulating markers of inflammation in the prediction of coronary heart disease. N Engl J Med. 2004;350:1387-1397.
38. Pearson TA, Mensah GA, Alexander RW, Anderson JL, Cannon RO 3rd, Criqui M, Fadl YY, Fortmann SP, Hong Y, Myers GL, Rifai N, Smith SC Jr, Taubert K, Tracy RP, Vinicor F; Centers for Disease Control and Prevention; American Heart Association. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499-511.
39. Puri R, Nissen SE, Libby P, Shao M, Ballantyne CM, Barter PJ, Chapman MJ, Erbel R, Raichlen JS, Uno K, Kataoka Y, Nicholls SJ. C-reactive protein, but not low-density lipoprotein cholesterol levels, associate with coronary atheroma regression and cardiovascular events after maximally intensive statin therapy. Circulation. 2013;128:2395-2403.
40. Bos MJ, Schipper CM, Koudstaal PJ, Witteman JC, Hofman A, Breteler MM. High serum C-reactive protein level is not an independent predictor for stroke: the Rotterdam Study. Circulation. 2006;114:1591-1598.
41. Rutter MK, Meigs JB, Sullivan LM, D'Agostino RB Sr, Wilson PW. C-reactive protein, the metabolic syndrome, and prediction of cardiovascular events in the Framingham Offspring Study. Circulation. 2004;110:380-385.
42. Libby P. Inflammation and cardiovascular disease mechanisms. Am J Clin Nutr. 2006;83:456S-460S.
43. Egger G, Dixon J. Inflammatory effects of nutritional stimuli: further support for the need for a big picture approach to tackling obesity and chronic disease. Obes Rev. 2010;11:137-149.
44. Libby P. Inflammation in atherosclerosis. Nature. 2002;420:868-874.
45. Ridker PM. C-reactive protein and the prediction of cardiovascular events among those at intermediate risk: moving an inflammatory hypothesis toward consensus. J Am Coll Cardiol. 2007;49:2129-2138.
46. Gulliford MC, Charlton J, Latinovic R. Risk of diabetes associated with prescribed glucocorticoids in a large population. Diabetes Care. 2006;29:2728-2729.
47. Marston L, Carpenter JR, Walters KR, Morris RW, Nazareth I, Petersen I. Issues in multiple imputation of missing data for large general practice clinical databases. Pharmacoepidemiol Drug Saf. 2010;19:618-626.
48. Donders AR, van der Heijden GJ, Stijnen T, Moons KG. Review: a gentle introduction to imputation of missing values. J Clin Epidemiol. 2006;59:1087-1091.
49. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J. 2009;51:171-184.